Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen
- PMID: 22949147
- DOI: 10.1200/JCO.2012.42.8201
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen
Abstract
Purpose: Treatment for metastatic colorectal cancer (mCRC) commonly involves a fluoropyrimidine-based chemotherapy regimen such as infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) or fluorouracil, leucovorin, and oxaliplatin, often combined with bevacizumab or an epidermal growth factor receptor monoclonal antibody. We studied the effect of adding the novel antiangiogenic agent aflibercept (also known as ziv-aflibercept in the United States) to FOLFIRI in patients with mCRC previously treated with oxaliplatin, including patients who received prior bevacizumab.
Patients and methods: Patients were randomly assigned to receive aflibercept (4 mg/kg intravenously; 612 patients) or placebo (614 patients) every 2 weeks in combination with FOLFIRI. Treatment was administered until disease progression or unacceptable toxicity. The primary end point was overall survival.
Results: Adding aflibercept to FOLFIRI significantly improved overall survival relative to placebo plus FOLFIRI (hazard ratio [HR], 0.817; 95.34% CI, 0.713 to 0.937; P = .0032) with median survival times of 13.50 versus 12.06 months, respectively. Aflibercept also significantly improved progression-free survival (PFS; HR, 0.758; 95% CI, 0.661 to 0.869; P < .0001), with median PFS times of 6.90 versus 4.67 months, respectively. The effects on overall survival and PFS exhibited a consistent trend across prespecified subgroup analyses, including bevacizumab pretreated patients. Response rate was 19.8% (95% CI, 16.4% to 23.2%) with aflibercept plus FOLFIRI compared with 11.1% (95% CI, 8.5% to 13.8%) with placebo plus FOLFIRI (P = .0001). Adverse effects reported with aflibercept combined with FOLFIRI included the characteristic anti-vascular endothelial growth factor effects and also reflected an increased incidence of some chemotherapy-related toxicities.
Conclusion: Aflibercept in combination with FOLFIRI conferred a statistically significant survival benefit over FOLFIRI combined with placebo in patients with mCRC previously treated with oxaliplatin.
Trial registration: ClinicalTrials.gov NCT00561470.
Similar articles
-
Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy.Target Oncol. 2016 Jun;11(3):383-400. doi: 10.1007/s11523-015-0402-9. Target Oncol. 2016. PMID: 26706237 Clinical Trial.
-
The Clinical and Cost Effectiveness of Aflibercept in Combination with Irinotecan and Fluorouracil-Based Therapy (FOLFIRI) for the Treatment of Metastatic Colorectal Cancer Which has Progressed Following Prior Oxaliplatin-Based Chemotherapy: a Critique of the Evidence.Pharmacoeconomics. 2015 May;33(5):457-66. doi: 10.1007/s40273-015-0257-z. Pharmacoeconomics. 2015. PMID: 25616671 Review.
-
Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial.Eur J Cancer. 2014 Jan;50(2):320-31. doi: 10.1016/j.ejca.2013.09.013. Epub 2013 Oct 16. Eur J Cancer. 2014. PMID: 24140268 Clinical Trial.
-
Chemotherapy of metastatic colorectal cancer.Prescrire Int. 2010 Oct;19(109):219-24. Prescrire Int. 2010. PMID: 21180382 Review.
-
Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.J Clin Oncol. 2007 Oct 20;25(30):4779-86. doi: 10.1200/JCO.2007.11.3357. J Clin Oncol. 2007. PMID: 17947725 Clinical Trial.
Cited by
-
Unveiling the anticancer potential of the ethanolic extract from Trichoderma asperelloides.Front Pharmacol. 2024 May 1;15:1398135. doi: 10.3389/fphar.2024.1398135. eCollection 2024. Front Pharmacol. 2024. PMID: 38751785 Free PMC article.
-
Real-World Evidence of FOLFIRI Combined with Anti-Angiogenesis Inhibitors or Anti-EGFR Antibodies for Patients with Early Recurrence Colorectal Cancer After Adjuvant FOLFOX/CAPOX Therapy: A Japanese Claims Database Study.Target Oncol. 2024 Jul;19(4):575-585. doi: 10.1007/s11523-024-01063-y. Epub 2024 May 1. Target Oncol. 2024. PMID: 38691296 Free PMC article.
-
First-Line LV5FU2 with or without Aflibercept in Patients with Non-Resectable Metastatic Colorectal Cancer: A Randomized Phase II Trial (PRODIGE 25-FFCD-FOLFA).Cancers (Basel). 2024 Apr 16;16(8):1515. doi: 10.3390/cancers16081515. Cancers (Basel). 2024. PMID: 38672597 Free PMC article.
-
Prediction of Response to Anti-Angiogenic Treatment for Advanced Colorectal Cancer Patients: From Biological Factors to Functional Imaging.Cancers (Basel). 2024 Mar 30;16(7):1364. doi: 10.3390/cancers16071364. Cancers (Basel). 2024. PMID: 38611042 Free PMC article. Review.
-
Sunglasses for Sunlight: Considerations on New Treatment Opportunities for Refractory Colorectal Cancer.Cancers (Basel). 2024 Mar 29;16(7):1348. doi: 10.3390/cancers16071348. Cancers (Basel). 2024. PMID: 38611026 Free PMC article.
Publication types
MeSH terms
Substances
Supplementary concepts
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials